Background: Raynaud's phenomenon (RP) represents one of the main features and causes
of comorbidity in patients with Systemic Sclerosis (SSc). Dihydropyridine calcium-channel …

Background Systemic Sclerosis (SSc) is a rare autoimmune disease with fibrosis, changes
in the skin, vasculature, joints and internal organs. Diffuse disease involves lung, heart and …

Objective Most patients with systemic sclerosis (SSc) have Raynaud's phenomenon (RP),
which is often more severe than idiopathic RP. This study was a meta‐analysis to determine …

The work carried out by the authors on calcium and the cardiovascular risk is of primary
importance. 1 We thank the authors for questions and comments on the Strontium ranelate …

Background: Aminaphtone (3-Methyl-1, 4-dioxo-1, 4-dihydro-naphthalen-2-y4-amino-
benzoate) is a chemical vasoactive compound licensed to treat microvascular disorders [1] …

Raynaud's phenomenon (RP) is present in more than 95% of patients with systemic
sclerosis (SSc). Its frequency and severity in combination with the presence of digital ulcers …

Background Raynaud9s phenomenon (RP) occurs in> 95% of patients (pts) with systemic
sclerosis (SSc) and contributes to digital ischaemia that may lead to digital ulcers (DUs) and …

We read with interest the paper by Hall and Buchbinder, 1 which discussed the importance
of accurate needle placement guided by imaging techniques in the therapeutic response to …

Background: Cardiovascular MRI (CMR) abnormalities can be detected in people with
rheumatoid arthritis (RA) and systemic sclerosis (SSc) in the absence of cardiac symptoms …

Background: Cardiac Magnetic Resonance Imaging (CMRI) with Late Gadolinium
Enhancement (LGE) has an established value in the diagnostic and prognostic assessment …